<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35787294</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2051-5960</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>04</Day></PubDate></JournalIssue><Title>Acta neuropathologica communications</Title><ISOAbbreviation>Acta Neuropathol Commun</ISOAbbreviation></Journal><ArticleTitle>Modulation of synaptic plasticity, motor unit physiology, and TDP-43 pathology by CHCHD10.</ArticleTitle><Pagination><StartPage>95</StartPage><MedlinePgn>95</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">95</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40478-022-01386-9</ELocationID><Abstract><AbstractText>Mutations in CHCHD10, a gene coding for a mitochondrial intermembrane space protein, are associated with Frontotemporal dementia (FTD)-Amyotrophic lateral sclerosis (ALS) spectrum disorders, which are pathologically characterized by cytoplasmic inclusions containing TDP-43. FTD/ALS-linked CHCHD10 mutations and TDP-43 inclusions similarly induce mitochondrial defects in respiration, fusion/fission, mtDNA stability, and cristae structure, while sizeable amounts of cytoplasmic TDP-43 aggregates are found in mitochondria. However, the mechanistic link between CHCHD10 and TDP-43 pathogenesis remains unclear. In this study, we present immunohistochemical and biochemical evidence demonstrating that insoluble CHCHD10 aggregates accumulate and colocalize with phospho-TDP-43 inclusions in brains of FTLD-TDP and AD patients, and that insoluble CHCHD10 levels tightly correlate with insoluble TDP-43 levels in control and FTLD-TDP brains. In an experimental exploration of this pathological phenotype, transgenic mice neuronally expressing FTD/ALS-linked CHCHD10<sup>R15L</sup> or CHCHD<sup>S59L</sup> mutations but not CHCHD10<sup>WT</sup> transgenic mice exhibit significantly increased CHCHD10 aggregation and phospho-TDP-43 pathology, which often colocalize within the same inclusions. Such pathologies are reflected in poor functional outcomes in long-term synaptic plasticity, motor unit physiology, and behavior in CHCHD10<sup>R15L</sup> and CHCHD<sup>S59L</sup> transgenic mice. In contrast, expression of CHCHD10<sup>WT</sup> in hTDP-43 transgenic mice (TAR4;CHCHD10<sup>WT</sup>) significantly mitigates phospho-TDP-43 pathology and rescues TDP-43-induced impairments in synaptic integrity and long-term synaptic plasticity. In isolated mitochondria, the S59L mutation induces the aggregation of resident CHCHD10<sup>S59L</sup> protein as well as the aggregation and slower turnover of recombinant TDP-43 imported into mitochondria. Likewise, in an in vitro cell-free system, the S59L mutation induces the aggregation of CHCHD10<sup>S59L</sup> protein while simultaneously enhancing the aggregation of recombinant TDP-43, as evidenced by filter trap assays and atomic force microscopy. In contrast, recombinant CHCHD10<sup>WT</sup> inhibits the growth of TDP-43 aggregates. These results in human brains, transgenic mice, and in vitro systems substantiate the role of wild type and mutant CHCHD10 in modulating mitochondrial CHCHD10 and TDP-43 pathogenesis together with associated phenotypes in long-term synaptic plasticity and motor unit physiology in mice and humans.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Tian</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH, 44106, USA. txl757@case.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woo</LastName><ForeName>Jung-A A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH, 44106, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Medicine, Byrd Alzheimer's Center &amp; Research Institute, USF Health Morsani College of Medicine, Tampa, FL, 33613, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bukhari</LastName><ForeName>Mohammed Zaheen</ForeName><Initials>MZ</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Byrd Alzheimer's Center &amp; Research Institute, USF Health Morsani College of Medicine, Tampa, FL, 33613, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xinming</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH, 44106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH, 44106, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Medicine, Byrd Alzheimer's Center &amp; Research Institute, USF Health Morsani College of Medicine, Tampa, FL, 33613, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buosi</LastName><ForeName>Sara Cazzaro</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH, 44106, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Medicine, Byrd Alzheimer's Center &amp; Research Institute, USF Health Morsani College of Medicine, Tampa, FL, 33613, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ermekbaeva</LastName><ForeName>Aizara</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Byrd Alzheimer's Center &amp; Research Institute, USF Health Morsani College of Medicine, Tampa, FL, 33613, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sista</LastName><ForeName>Apoorva</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Byrd Alzheimer's Center &amp; Research Institute, USF Health Morsani College of Medicine, Tampa, FL, 33613, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotsiviras</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Byrd Alzheimer's Center &amp; Research Institute, USF Health Morsani College of Medicine, Tampa, FL, 33613, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>LePochat</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Byrd Alzheimer's Center &amp; Research Institute, USF Health Morsani College of Medicine, Tampa, FL, 33613, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chacko</LastName><ForeName>Ann</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Byrd Alzheimer's Center &amp; Research Institute, USF Health Morsani College of Medicine, Tampa, FL, 33613, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Xingyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Byrd Alzheimer's Center &amp; Research Institute, USF Health Morsani College of Medicine, Tampa, FL, 33613, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>David E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH, 44106, USA. dek94@case.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Louis Strokes Cleveland VA Medical Center, Cleveland, OH, USA. dek94@case.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Medicine, Byrd Alzheimer's Center &amp; Research Institute, USF Health Morsani College of Medicine, Tampa, FL, 33613, USA. dek94@case.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>I01 BX004680</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG070299</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 BX002478</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS073899</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS122350</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG053060</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Acta Neuropathol Commun</MedlineTA><NlmUniqueID>101610673</NlmUniqueID><ISSNLinking>2051-5960</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C554426">CHCHD10 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578077">TDP-43 protein, mouse</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C566288">Frontotemporal Dementia With Motor Neuron Disease</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CHCHD10</Keyword><Keyword MajorTopicYN="N">Frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">Mitochondria</Keyword><Keyword MajorTopicYN="N">Synapse</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>5</Day><Hour>17</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35787294</ArticleId><ArticleId IdType="pmc">PMC9254494</ArticleId><ArticleId IdType="doi">10.1186/s40478-022-01386-9</ArticleId><ArticleId IdType="pii">10.1186/s40478-022-01386-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Rademakers R. The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia. Curr Opin Neurol. 2008;21(6):693&#x2013;700. doi: 10.1097/WCO.0b013e3283168d1d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0b013e3283168d1d</ArticleId><ArticleId IdType="pmc">PMC2869081</ArticleId><ArticleId IdType="pubmed">18989115</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Bioph Res Co. 2006;351(3):602&#x2013;611. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Whitwell JL, Weigand SD, et al. TDP-43 is a key player in the clinical features associated with Alzheimer's disease. Acta Neuropathol. 2014;127(6):811&#x2013;824. doi: 10.1007/s00401-014-1269-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1269-z</ArticleId><ArticleId IdType="pmc">PMC4172544</ArticleId><ArticleId IdType="pubmed">24659241</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Dickson DW, Trojanowski JQ, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142(6):1503&#x2013;1527. doi: 10.1093/brain/awz099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz099</ArticleId><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Kwong LK, Lee EB, et al. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 2009;117(2):137&#x2013;149. doi: 10.1007/s00401-008-0477-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0477-9</ArticleId><ArticleId IdType="pmc">PMC2693625</ArticleId><ArticleId IdType="pubmed">19125255</ArticleId></ArticleIdList></Reference><Reference><Citation>Cykowski MD, Powell SZ, Appel JW, Arumanayagam AS, Rivera AL, Appel SH. Phosphorylated TDP-43 (pTDP-43) aggregates in the axial skeletal muscle of patients with sporadic and familial amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2018;6(1):28. doi: 10.1186/s40478-018-0528-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0528-y</ArticleId><ArticleId IdType="pmc">PMC5899326</ArticleId><ArticleId IdType="pubmed">29653597</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology. 2002;59(7):1077&#x2013;1079. doi: 10.1212/wnl.59.7.1077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.59.7.1077</ArticleId><ArticleId IdType="pubmed">12370467</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Gray E, Ansorge O, Talbot K, Turner MR. Towards a TDP-43-based biomarker for ALS and FTLD. Mol Neurobiol. 2018;55(10):7789&#x2013;7801. doi: 10.1007/s12035-018-0947-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-0947-6</ArticleId><ArticleId IdType="pmc">PMC6132775</ArticleId><ArticleId IdType="pubmed">29460270</ArticleId></ArticleIdList></Reference><Reference><Citation>Muyderman H, Chen T. Mitochondrial dysfunction in amyotrophic lateral sclerosis: a valid pharmacological target? Br J Pharmacol. 2014;171(8):2191&#x2013;2205. doi: 10.1111/bph.12476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.12476</ArticleId><ArticleId IdType="pmc">PMC3976630</ArticleId><ArticleId IdType="pubmed">24148000</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EF, Shaw PJ, De Vos KJ. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci Lett. 2017 doi: 10.1016/j.neulet.2017.06.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2017.06.052</ArticleId><ArticleId IdType="pubmed">28669745</ArticleId></ArticleIdList></Reference><Reference><Citation>Borthwick GM, Johnson MA, Ince PG, Shaw PJ, Turnbull DM. Mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death. Ann Neurol. 1999;46(5):787&#x2013;790. doi: 10.1002/1531-8249(199911)46:5&lt;787::AID-ANA17&gt;3.0.CO;2-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1531-8249(199911)46:5&lt;787::AID-ANA17&gt;3.0.CO;2-8</ArticleId><ArticleId IdType="pubmed">10553999</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Deng J, Dong J, et al. TDP-43 induces mitochondrial damage and activates the mitochondrial unfolded protein response. PLoS Genet. 2019;15(5):e1007947. doi: 10.1371/journal.pgen.1007947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1007947</ArticleId><ArticleId IdType="pmc">PMC6524796</ArticleId><ArticleId IdType="pubmed">31100073</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu YF, Gendron TF, Zhang YJ, et al. Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J Neurosci. 2010;30(32):10851&#x2013;10859. doi: 10.1523/JNEUROSCI.1630-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1630-10.2010</ArticleId><ArticleId IdType="pmc">PMC3056148</ArticleId><ArticleId IdType="pubmed">20702714</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S, Takeda T, Shibata N, Kobayashi M. Alterations in subcellular localization of TDP-43 immunoreactivity in the anterior horns in sporadic amyotrophic lateral sclerosis. Neurosci Lett. 2010;478(2):72&#x2013;76. doi: 10.1016/j.neulet.2010.04.068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2010.04.068</ArticleId><ArticleId IdType="pubmed">20447446</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Wang L, Lu J, et al. The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity. Nat Med. 2016;22(8):869&#x2013;878. doi: 10.1038/nm.4130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4130</ArticleId><ArticleId IdType="pmc">PMC4974139</ArticleId><ArticleId IdType="pubmed">27348499</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo JA, Liu T, Trotter C, et al. Loss of function CHCHD10 mutations in cytoplasmic TDP-43 accumulation and synaptic integrity. Nat Commun. 2017;8:15558. doi: 10.1038/ncomms15558.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms15558</ArticleId><ArticleId IdType="pmc">PMC5467170</ArticleId><ArticleId IdType="pubmed">28585542</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang TC, Handley E, Brizuela M, et al. Amyotrophic lateral sclerosis mutant TDP-43 may cause synaptic dysfunction through altered dendritic spine function. Dis Model Mech. 2019 doi: 10.1242/dmm.038109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.038109</ArticleId><ArticleId IdType="pmc">PMC6550035</ArticleId><ArticleId IdType="pubmed">31036551</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang WZ, Arakawa H, Wang LW, et al. Motor-coordinative and cognitive dysfunction caused by mutant TDP-43 could be reversed by inhibiting its mitochondrial localization. Mol Ther. 2017;25(1):127&#x2013;139. doi: 10.1016/j.ymthe.2016.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2016.10.013</ArticleId><ArticleId IdType="pmc">PMC5363201</ArticleId><ArticleId IdType="pubmed">28129109</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J, Wang LW, Yan TX, Perry G, Wang XL. TDP-43 proteinopathy and mitochondrial abnormalities in neurodegeneration. Mol Cell Neurosci. 2019 doi: 10.1016/j.mcn.2019.103396.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2019.103396</ArticleId><ArticleId IdType="pmc">PMC6874890</ArticleId><ArticleId IdType="pubmed">31445085</ArticleId></ArticleIdList></Reference><Reference><Citation>Bannwarth S, Ait-El-Mkadem S, Chaussenot A, et al. A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. Brain. 2014;137(Pt 8):2329&#x2013;2345. doi: 10.1093/brain/awu138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu138</ArticleId><ArticleId IdType="pmc">PMC4107737</ArticleId><ArticleId IdType="pubmed">24934289</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JO, Glynn SM, Gibbs JR, et al. Mutations in the CHCHD10 gene are a common cause of familial amyotrophic lateral sclerosis. Brain. 2014;137(Pt 12):e311. doi: 10.1093/brain/awu265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu265</ArticleId><ArticleId IdType="pmc">PMC4240285</ArticleId><ArticleId IdType="pubmed">25261972</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller K, Andersen PM, Hubers A, et al. Two novel mutations in conserved codons indicate that CHCHD10 is a gene associated with motor neuron disease. Brain. 2014;137(Pt 12):e309. doi: 10.1093/brain/awu227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu227</ArticleId><ArticleId IdType="pubmed">25113787</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Xi Z, Zinman L, et al. Mutation analysis of CHCHD10 in different neurodegenerative diseases. Brain. 2015;138(Pt 9):e380. doi: 10.1093/brain/awv082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv082</ArticleId><ArticleId IdType="pmc">PMC4547051</ArticleId><ArticleId IdType="pubmed">25833818</ArticleId></ArticleIdList></Reference><Reference><Citation>Burstein SR, Valsecchi F, Kawamata H, et al. In vitro and in vivo studies of the ALS-FTLD protein CHCHD10 reveal novel mitochondrial topology and protein interactions. Hum Mol Genet. 2018;27(1):160&#x2013;177. doi: 10.1093/hmg/ddx397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx397</ArticleId><ArticleId IdType="pmc">PMC5886281</ArticleId><ArticleId IdType="pubmed">29112723</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T, Woo JA, Bukhari MZ, et al. CHCHD10-regulated OPA1-mitofilin complex mediates TDP-43-induced mitochondrial phenotypes associated with frontotemporal dementia. FASEB J. 2020 doi: 10.1096/fj.201903133RR.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201903133RR</ArticleId><ArticleId IdType="pmc">PMC7482311</ArticleId><ArticleId IdType="pubmed">32369233</ArticleId></ArticleIdList></Reference><Reference><Citation>Genin EC, Bannwarth S, Lespinasse F, et al. Loss of MICOS complex integrity and mitochondrial damage, but not TDP-43 mitochondrial localisation, are likely associated with severity of CHCHD10-related diseases. Neurobiol Dis. 2018;119:159&#x2013;171. doi: 10.1016/j.nbd.2018.07.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.07.027</ArticleId><ArticleId IdType="pmc">PMC7015038</ArticleId><ArticleId IdType="pubmed">30092269</ArticleId></ArticleIdList></Reference><Reference><Citation>Genin EC, Plutino M, Bannwarth S, et al. CHCHD10 mutations promote loss of mitochondrial cristae junctions with impaired mitochondrial genome maintenance and inhibition of apoptosis. Embo Mol Med. 2016;8(1):58&#x2013;72. doi: 10.15252/emmm.201505496.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201505496</ArticleId><ArticleId IdType="pmc">PMC4718158</ArticleId><ArticleId IdType="pubmed">26666268</ArticleId></ArticleIdList></Reference><Reference><Citation>Wils H, Kleinberger G, Janssens J, et al. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A. 2010;107(8):3858&#x2013;3863. doi: 10.1073/pnas.0912417107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0912417107</ArticleId><ArticleId IdType="pmc">PMC2840518</ArticleId><ArticleId IdType="pubmed">20133711</ArticleId></ArticleIdList></Reference><Reference><Citation>van Waarde-Verhagen M, Kampinga HH. Measurement of chaperone-mediated effects on polyglutamine protein aggregation by the filter trap assay. Methods Mol Biol. 2018;1709:59&#x2013;74. doi: 10.1007/978-1-4939-7477-1_5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-7477-1_5</ArticleId><ArticleId IdType="pubmed">29177651</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo JA, Liu T, Zhao X, et al. Enhanced tau pathology via RanBP9 and Hsp90/Hsc70 chaperone complexes. Hum Mol Genet. 2017;26(20):3973&#x2013;3988. doi: 10.1093/hmg/ddx284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx284</ArticleId><ArticleId IdType="pmc">PMC6075219</ArticleId><ArticleId IdType="pubmed">29016855</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan EB, Yan J, Miller N, et al. Early death of ALS-linked CHCHD10-R15L transgenic mice with central nervous system, skeletal muscle, and cardiac pathology. iScience. 2021;24(2):102061. doi: 10.1016/j.isci.2021.102061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2021.102061</ArticleId><ArticleId IdType="pmc">PMC7890413</ArticleId><ArticleId IdType="pubmed">33659869</ArticleId></ArticleIdList></Reference><Reference><Citation>Genin EC, Madji Hounoum B, Bannwarth S, et al. Mitochondrial defect in muscle precedes neuromuscular junction degeneration and motor neuron death in CHCHD10(S59L/+) mouse. Acta Neuropathol. 2019 doi: 10.1007/s00401-019-01988-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-01988-z</ArticleId><ArticleId IdType="pubmed">30874923</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmer C, Schludi MH, Ransom L, et al. A novel CHCHD10 mutation implicates a Mia40-dependent mitochondrial import deficit in ALS. Embo Mol Med. 2018 doi: 10.15252/emmm.201708558.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201708558</ArticleId><ArticleId IdType="pmc">PMC5991575</ArticleId><ArticleId IdType="pubmed">29789341</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson CJ, Bredvik K, Burstein SR, et al. ALS/FTD mutant CHCHD10 mice reveal a tissue-specific toxic gain-of-function and mitochondrial stress response. Acta Neuropathol. 2019 doi: 10.1007/s00401-019-01989-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-01989-y</ArticleId><ArticleId IdType="pmc">PMC6571048</ArticleId><ArticleId IdType="pubmed">30877432</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Xu YF, Cook C, et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci USA. 2009;106(18):7607&#x2013;7612. doi: 10.1073/pnas.0900688106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0900688106</ArticleId><ArticleId IdType="pmc">PMC2671323</ArticleId><ArticleId IdType="pubmed">19383787</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Albuquerque CP, Han JS, et al. ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. Proc Natl Acad Sci USA. 2010;107(30):13318&#x2013;13323. doi: 10.1073/pnas.1008227107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1008227107</ArticleId><ArticleId IdType="pmc">PMC2922163</ArticleId><ArticleId IdType="pubmed">20624952</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Q, Tammineni P. Mitochondrial aspects of synaptic dysfunction in Alzheimer's disease. J Alzheimers Dis. 2017;57(4):1087&#x2013;1103. doi: 10.3233/JAD-160726.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160726</ArticleId><ArticleId IdType="pmc">PMC5398949</ArticleId><ArticleId IdType="pubmed">27767992</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CW, Peng HB. The function of mitochondria in presynaptic development at the neuromuscular junction. Mol Biol Cell. 2008;19(1):150&#x2013;158. doi: 10.1091/mbc.E07-05-0515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.E07-05-0515</ArticleId><ArticleId IdType="pmc">PMC2174173</ArticleId><ArticleId IdType="pubmed">17942598</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng ZH. Mitochondrial trafficking and anchoring in neurons: New insight and implications. J Cell Biol. 2014;204(7):1087&#x2013;1098. doi: 10.1083/jcb.201312123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201312123</ArticleId><ArticleId IdType="pmc">PMC3971748</ArticleId><ArticleId IdType="pubmed">24687278</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaper DC, Adachi Y, Sutcliffe B, et al. Loss and gain of Drosophila TDP-43 impair synaptic efficacy and motor control leading to age-related neurodegeneration by loss-of-function phenotypes. Hum Mol Genet. 2013;22(8):1539&#x2013;1557. doi: 10.1093/hmg/ddt005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt005</ArticleId><ArticleId IdType="pmc">PMC3605831</ArticleId><ArticleId IdType="pubmed">23307927</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebstein SY, Yagudayeva I, Shneider NA. Mutant TDP-43 causes early-stage dose-dependent motor neuron degeneration in a TARDBP Knockin Mouse Model of ALS. Cell Rep. 2019;26(2):364&#x2013;373 e4. doi: 10.1016/j.celrep.2018.12.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.12.045</ArticleId><ArticleId IdType="pubmed">30625319</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo JA, Zhao X, Khan H, et al. Slingshot-Cofilin activation mediates mitochondrial and synaptic dysfunction via Abeta ligation to beta1-integrin conformers. Cell Death Differ. 2015;22(6):921&#x2013;934. doi: 10.1038/cdd.2015.5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2015.5</ArticleId><ArticleId IdType="pmc">PMC4423195</ArticleId><ArticleId IdType="pubmed">25698445</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold WD, Sheth KA, Wier CG, Kissel JT, Burghes AH, Kolb SJ. Electrophysiological motor unit number estimation (MUNE) measuring compound muscle action potential (CMAP) in mouse Hindlimb muscles. J Vis Exp. 2015 doi: 10.3791/52899.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/52899</ArticleId><ArticleId IdType="pmc">PMC4676269</ArticleId><ArticleId IdType="pubmed">26436455</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngo ST, Baumann F, Ridall PG, et al. The relationship between Bayesian motor unit number estimation and histological measurements of motor neurons in wild-type and SOD1(G93A) mice. Clin Neurophysiol. 2012;123(10):2080&#x2013;2091. doi: 10.1016/j.clinph.2012.01.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2012.01.028</ArticleId><ArticleId IdType="pubmed">22521362</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Rutkove SB. Neurophysiological biomarkers in amyotrophic lateral sclerosis. Curr Opin Neurol. 2018;31(5):640&#x2013;647. doi: 10.1097/WCO.0000000000000593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000593</ArticleId><ArticleId IdType="pubmed">30080715</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz LM, Kwong LK, Chen-Plotkin A, et al. Expression of TDP-43 C-terminal fragments in vitro recapitulates pathological features of TDP-43 Proteinopathies. J Biol Chem. 2009;284(13):8516&#x2013;8524. doi: 10.1074/jbc.M809462200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M809462200</ArticleId><ArticleId IdType="pmc">PMC2659210</ArticleId><ArticleId IdType="pubmed">19164285</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, Tan W, Whittle C, et al. The C-terminal TDP-43 fragments have a high aggregation propensity and harm neurons by a dominant-negative mechanism. PLoS ONE. 2010;5(12):e15878. doi: 10.1371/journal.pone.0015878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0015878</ArticleId><ArticleId IdType="pmc">PMC3013128</ArticleId><ArticleId IdType="pubmed">21209826</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Xu YF, Cook C, et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci U S A. 2009;106(18):7607&#x2013;7612. doi: 10.1073/pnas.0900688106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0900688106</ArticleId><ArticleId IdType="pmc">PMC2671323</ArticleId><ArticleId IdType="pubmed">19383787</ArticleId></ArticleIdList></Reference><Reference><Citation>Bannwarth S, Ait-El-Mkadem S, Chaussenot A, et al. A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. Brain. 2014;137:2329&#x2013;2345. doi: 10.1093/brain/awu138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu138</ArticleId><ArticleId IdType="pmc">PMC4107737</ArticleId><ArticleId IdType="pubmed">24934289</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan L, Zhou C, Jin E, et al. Cytosolic proteostasis through importing of misfolded proteins into mitochondria. Nature. 2017;543(7645):443&#x2013;446. doi: 10.1038/nature21695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21695</ArticleId><ArticleId IdType="pmc">PMC5793917</ArticleId><ArticleId IdType="pubmed">28241148</ArticleId></ArticleIdList></Reference><Reference><Citation>Laferriere F, Maniecka Z, Perez-Berlanga M, et al. TDP-43 extracted from frontotemporal lobar degeneration subject brains displays distinct aggregate assemblies and neurotoxic effects reflecting disease progression rates. Nat Neurosci. 2019;22(1):65&#x2013;77. doi: 10.1038/s41593-018-0294-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0294-y</ArticleId><ArticleId IdType="pubmed">30559480</ArticleId></ArticleIdList></Reference><Reference><Citation>Baek M, Choe YJ, Bannwarth S, et al. TDP-43 and PINK1 mediate CHCHD10(S59L) mutation-induced defects in Drosophila and in vitro. Nat Commun. 2021;12(1):1924. doi: 10.1038/s41467-021-22145-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-22145-9</ArticleId><ArticleId IdType="pmc">PMC7997989</ArticleId><ArticleId IdType="pubmed">33772006</ArticleId></ArticleIdList></Reference><Reference><Citation>Keith JL, Swinkin E, Gao A, et al. Neuropathologic description of CHCHD10 mutated amyotrophic lateral sclerosis. Neurol Genet. 2020;6(1):e394. doi: 10.1212/NXG.0000000000000394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000394</ArticleId><ArticleId IdType="pmc">PMC6975173</ArticleId><ArticleId IdType="pubmed">32042922</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajroud-Driss S, Fecto F, Ajroud K, et al. Mutation in the novel nuclear-encoded mitochondrial protein CHCHD10 in a family with autosomal dominant mitochondrial myopathy. Neurogenetics. 2015;16(1):1&#x2013;9. doi: 10.1007/s10048-014-0421-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10048-014-0421-1</ArticleId><ArticleId IdType="pmc">PMC4796476</ArticleId><ArticleId IdType="pubmed">25193783</ArticleId></ArticleIdList></Reference><Reference><Citation>Penttila S, Jokela M, Bouquin H, Saukkonen AM, Toivanen J, Udd B. Late onset spinal motor neuronopathy is caused by mutation in CHCHD10. Ann Neurol. 2015;77(1):163&#x2013;172. doi: 10.1002/ana.24319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24319</ArticleId><ArticleId IdType="pubmed">25428574</ArticleId></ArticleIdList></Reference><Reference><Citation>Auranen M, Ylikallio E, Shcherbii M, et al. CHCHD10 variant p.(Gly66Val) causes axonal Charcot-Marie-Tooth disease. Neurol Genet. 2015;1(1):e1. doi: 10.1212/NXG.0000000000000003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000003</ArticleId><ArticleId IdType="pmc">PMC4821082</ArticleId><ArticleId IdType="pubmed">27066538</ArticleId></ArticleIdList></Reference><Reference><Citation>Dringenberg HC. The history of long-term potentiation as a memory mechanism: Controversies, confirmation, and some lessons to remember. Hippocampus. 2020;30(9):987&#x2013;1012. doi: 10.1002/hipo.23213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hipo.23213</ArticleId><ArticleId IdType="pubmed">32442358</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>